Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis.

Autor:	Otsuka E; Department of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.; Nagasaki Renal Center, Nagasaki, Japan., Kitamura M; Department of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.; Nagasaki Renal Center, Nagasaki, Japan., Funakoshi S; Nagasaki Renal Center, Nagasaki, Japan., Mukae H; Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan., Nishino T; Department of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Jazyk:	angličtina
Zdroj:	Frontiers in pharmacology [Front Pharmacol] 2024 May 30; Vol. 15, pp. 1362242. Date of Electronic Publication: 2024 May 30 (Print Publication: 2024).
DOI:	10.3389/fphar.2024.1362242
Abstrakt:	Background: Tirzepatide-a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist-is used to treat type 2 diabetes. However, the efficacy and safety of tirzepatide in patients undergoing hemodialysis remain unclear. Methods: We conducted a single-center retrospective study of patients with type 2 diabetes undergoing hemodialysis who were transitioned from dulaglutide to tirzepatide. We continuously monitored glucose levels in patients undergoing hemodialysis before and after switching from dulaglutide to tirzepatide. Results: Fourteen patients (mean age: 61.9 ± 9.9 years, male: female = 11:3) were included in this study. After switching to tirzepatide, time in range increased to 50.8% from 42.7% ( p = 0.02), time above range decreased to 37.8% from 48.4% ( p = 0.02), and mean glucose levels decreased to 137.4 mg/dL from 156.6 mg/dL ( p = 0.006). In contrast, there was no significant difference in time below range before and after tirzepatide administration (11.3% and 8.9%) ( p = 0.75). Three patients experienced dyspepsia (21.4%), and one patient experienced nausea (7.1%); however, no critical adverse events were reported. Conclusion: Transitioning from dulaglutide to tirzepatide improved glycemic control without increasing hypoglycemia in patients undergoing hemodialysis for type 2 diabetes. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Otsuka, Kitamura, Funakoshi, Mukae and Nishino.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu